Clinical trial monitoring (CTM) and auditing are both essential quality management activities, but they serve distinct purposes throughout the research lifecycle.
Monitoring provides ongoing oversight of trial conduct, participant safety, protocol compliance, and data integrity, while auditing provides an independent quality assurance (QA) assessment of trial activities and quality systems.
Sponsors, contract research organizations (CROs), and research sites can strengthen compliance, protect participants, and maintain inspection readiness by understanding the key differences between monitoring and auditing, the types of monitoring visits, how to prepare for a clinical trial audit, and answers to frequently asked questions about both activities.
What is clinical trial monitoring?
Under International Council for Harmonisation Efficacy Guideline 6 (Revision 3) (ICH E6[R3]), CTM is the process of overseeing a clinical trial’s progress and confirming that it’s conducted, recorded, and reported according to the protocol, standard operating procedures (SOPs), Good Clinical Practice (GCP), and applicable regulatory requirements.
Monitoring helps ensure that:
- Participants’ rights, safety, and well-being are protected.
- Trial data are accurate, complete, and verifiable.
- The study follows the approved protocol.
- Informed consent and safety reporting requirements are met.
- Investigational product is managed appropriately.
- Identified issues receive follow-up.
Clinical research associates (CRAs) commonly perform monitoring on behalf of the sponsor, although other qualified sponsor or CRO representatives may also participate. They review trial conduct, verify data, identify protocol deviations, document findings, and work with sites to resolve issues. Monitoring begins before enrollment and continues through study close-out.
While routine monitoring provides ongoing oversight throughout the study, risk-based monitoring—a targeted approach that concentrates resources on higher-risk areas—adjusts the frequency and scope of activities according to identified risks. A site with recurring consent errors, protocol deviations, or data quality concerns may require more frequent or focused review, while a consistently performing site may require fewer on-site visits alongside remote or centralized oversight.
What are the different types of clinical trial monitoring visits?
Different types of monitoring visits occur throughout the study lifecycle because site needs and trial risks change from selection through completion.
Site qualification visit (SQV)
An SQV assesses whether a research site is suitable for the proposed trial. The reviewer may evaluate staff experience, facilities, equipment, access to the target patient population, enrollment capacity, and the site’s ability to meet protocol and regulatory requirements.
Site initiation visit (SIV)
An SIV occurs after site selection and before participant enrollment. Its purpose is to train the study team and confirm readiness to begin the trial.
The CRA or sponsor representative may review the protocol, informed consent process, safety reporting, investigational product procedures, data-entry expectations, essential documents, and study-specific systems. The visit also confirms that required approvals, supplies, training, and documentation are in place.
Routine monitoring visit (RMV)
An RMV occurs during trial conduct and may be performed on site, remotely, or through a combination of approaches.
The review may examine participant documentation and reported data, protocol and safety compliance, investigational product accountability, essential study records, and unresolved findings. Routine monitoring helps identify concerns before they become systemic or affect additional participants or data.
For-cause monitoring (FCM) visit
An FCM visit is triggered by a specific concern rather than the standard monitoring schedule. Triggers may include protocol deviations, safety concerns, unusual data patterns, inadequate investigational product controls, or data quality issues.
The visit may focus on one process or expand if the concern suggests a broader compliance or quality problem.
Close-out visit (COV)
A COV verifies study completion and confirms that outstanding responsibilities have been addressed. The review may cover final data queries, document retention, essential-document completeness, investigational product disposition, and remaining follow-up actions.
What is a clinical trial audit?
A clinical trial audit is an independent QA assessment of trial-related activities, records, systems, or facilities. It determines whether those activities were conducted and documented according to the protocol, organizational procedures, GCP, and applicable regulatory requirements.
Audits may be internal or external. A sponsor’s independent QA function may conduct an internal audit, while a qualified third party may perform an external audit of a research site, CRO, laboratory, technology provider, or other vendor. By identifying compliance gaps before a regulatory inspection, audits support inspection readiness.
Organizational independence is a defining feature of auditing. Auditors should remain separate from the activities they assess so they can objectively evaluate individual study conduct or the quality systems supporting multiple studies and processes.
Audit findings are generally documented in a formal report. Significant observations may require corrective and preventive actions (CAPAs) to address immediate problems, identify root causes, and reduce the likelihood of recurrence.
Monitoring vs. auditing: Key differences
The primary difference between monitoring and auditing in clinical trials is that monitoring provides ongoing oversight, while auditing provides an independent quality assessment.
| Area | Monitoring | Auditing |
| Primary purpose | Ongoing oversight | Independent quality assessment |
| Timing | Throughout the study | Periodically or at key milestones |
| Conducted by | CRA or sponsor representative | Independent QA auditor |
| Focus | Protocol compliance and data quality | Quality systems and regulatory compliance |
| Independence | No | Yes |
| Outcome | Findings and follow-up actions | Audit report and CAPAs |
Monitoring can’t replace auditing because routine oversight doesn’t provide the same independence or system-level assessment, and auditing can’t replace monitoring because periodic assessments don’t provide the continuous oversight needed to manage trial conduct and site performance.
How can research sites prepare for a clinical trial audit?
The best way to prepare for a clinical trial audit is to maintain continuous audit readiness rather than rely on last-minute preparation.
Research sites should:
- Maintain complete essential documents and regulatory binders.
- Keep delegation logs and training records current.
- Review informed consent documentation and protocol deviations.
- Reconcile investigational product accountability records.
- Confirm safety-reporting documentation is complete.
- Review electronic systems and access controls.
- Perform internal quality reviews.
- Develop and track CAPAs for significant or recurring issues.
Site staff should also understand how study activities were performed and know where supporting documentation is located. Inspection readiness depends on complete records and consistently controlled processes.
Why sponsors need both monitoring and auditing
Sponsors need both monitoring and auditing to support risk-based quality management, vendor oversight, and inspection readiness.
Monitoring provides timely visibility into trial execution and can identify site-level concerns such as repeated protocol deviations, incomplete documentation, or delayed data entry. Auditing evaluates whether the broader quality framework and regulatory controls are operating effectively.
Together, these activities help sponsors identify study-specific and systemic risks, strengthen vendor oversight, and demonstrate proactive quality management.
Frequently asked questions about clinical trial monitoring and auditing
Monitoring and auditing support proactive quality management
Monitoring and auditing are distinct but complementary. Monitoring provides ongoing oversight of study conduct and site performance, while auditing independently evaluates quality systems and regulatory compliance.
By integrating both activities into a proactive, risk-based quality management strategy, sponsors, CROs, and research sites can strengthen compliance, protect participants, and maintain inspection readiness.
Want to learn more? Check out this overview of Advarra’s CTM, QA, and inspection readiness resources, or contact us to ask an expert a specific question.
